Beijing Immunochina Pharmaceuticals Co.
Latest round
- Series E
Last raised
- Jan 2025
Total raised
- $43M
Investors
- 21
About Beijing Immunochina Pharmaceuticals Co.
, Ltd. operates as an immune cell therapy institution that provides cancer diagnosis and treatment services based on immune cell therapy. It has manufacturing facilities and production and testing facilities, which meet the regulations of China, the US, and the EU. The expert team of the company are from Peking University Third Hospital, Peking University Institute of Hematology and Peking University Cancer Hospital. In 2020, its product IM19 for lymphocytic leukemia and non-Hodgkin's lymphoma received two IND approvals. The company mainly engages in the research and development of malignant tumor treatment using gene cell drug technology. It develops gene vector scaling platform, T cell research, and scaling platform, and gene and cell drug analysis platform. Its R&D pipeline covers hematological tumors and solid tumors, including lymphoma, leukemia, liver cancer and colorectal cancer. Besides, the company is developing IM19 for diffuse large B cell lymphomas, and mantle cell lymphoma, IM21 for multiple myeloma, and IM23 for acute myeloid leukemia. The company generates revenue by developing tumor treatment drugs for liver cancer, stomach cancer, pancreatic cancer and other diseases.
Who invested in Beijing Immunochina Pharmaceuticals Co.
21 investors across 9 rounds
See all investors in Beijing Immunochina Pharmaceuticals Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
Jan 8, 2025
Amount
Undisclosed
Investors
Series D
Nov 1, 2022
Amount
Undisclosed
Investors
Series D
Nov 24, 2021
Amount
Undisclosed
Investors
Series C
Dec 22, 2020
Amount
Undisclosed
Investors
Series C
Oct 16, 2020
Amount
$15M
Investors
Series C
Jan 22, 2019
Amount
$21M
Investors
Series B
Oct 12, 2017
Amount
$7.6M
Investors
Series A
Mar 3, 2016
Amount
Undisclosed
Investors
Angel
Jun 2, 2015
Amount
Undisclosed
Investors
Questions about Beijing Immunochina Pharmaceuticals Co.
Who invested in Beijing Immunochina Pharmaceuticals Co.?
Beijing Immunochina Pharmaceuticals Co. has 21 investors on record across 9 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beijing Immunochina Pharmaceuticals Co. raised?
Beijing Immunochina Pharmaceuticals Co. has raised 9 venture rounds. Sign up free to see how much each round raised and the total.
When did Beijing Immunochina Pharmaceuticals Co. last raise money?
Beijing Immunochina Pharmaceuticals Co.'s most recent round on record is a Series E, in Jan 2025.
What does Beijing Immunochina Pharmaceuticals Co. do?
Beijing Immunochina Pharmaceuticals Co. is a biotechnology company.
Where is Beijing Immunochina Pharmaceuticals Co. headquartered?
Beijing Immunochina Pharmaceuticals Co. is headquartered in Beijing, China.
Which VCs invest in companies like Beijing Immunochina Pharmaceuticals Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Beijing Immunochina Pharmaceuticals Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Beijing Immunochina Pharmaceuticals Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.